Mazdutide

Mazdutide
Clinical data
Other names	IBI362; LY3305677
Routes of; administration	Injection
Legal status
Legal status	Rx in China, Investigational in general;
Identifiers
	IUPAC name 20-[[(1S)-4-[2-[2-[2-[2-[2-[2-[[(5S)-5-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3R)-2-[[2-[[(2S)-5-amino-2-[[2-[[(2S)-2-amino-3-(1H-imidazol-4-yl)propanoyl]amino]-2-methylpropanoyl]amino]-5-oxopentanoyl]amino]acetyl]amino]-3-hydroxybutanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxypropanoyl]amino]hexanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-3-carboxypropanoyl]amino]-4-carboxybutanoyl]amino]hexanoyl]amino]hexanoyl]amino]propanoyl]amino]-6-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[[2-[(2S)-2-[[(2S)-1-[(2-amino-2-oxoethyl)amino]-3-hydroxy-1-oxopropan-2-yl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]amino]-2-oxoethyl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-6-oxohexyl]amino]-2-oxoethoxy]ethoxy]ethylamino]-2-oxoethoxy]ethoxy]ethylamino]-1-carboxy-4-oxobutyl]amino]-20-oxoicosanoic acid;
CAS Number	2259884-03-0;
PubChem CID	167312357;
DrugBank	DB19099;
ChemSpider	129341158;
UNII	MB76Z4IBZ5;
Chemical and physical data
Formula	C210H322N46O67
Molar mass	4563.141 g·mol−1
	SMILES CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CC[C@H](NC(=O)CCCCCCCCCCCCCCCCCCC(=O)O)C(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)C(C)(C)NC(=O)[C@@H](N)Cc1c[nH]cn1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(N)=O;
	InChI InChI=1S/C210H322N46O67/c1-117(2)93-145(191(300)233-139(70-76-170(276)277)181(290)224-107-164(269)222-109-168(273)256-86-46-57-159(256)204(313)249-157(112-259)203(312)247-155(110-257)183(292)223-106-161(216)266)237-192(301)146(94-118(3)4)239-196(305)152(100-128-104-221-134-52-37-36-51-132(128)134)243-190(299)143(73-79-173(282)283)236-205(314)176(120(7)8)253-199(308)150(96-124-47-30-28-31-48-124)241-189(298)142(72-78-172(280)281)234-185(294)136(56-41-45-83-218-166(271)114-322-91-90-321-88-85-220-167(272)115-323-92-89-320-87-84-219-162(267)75-69-144(208(317)318)228-163(268)58-34-26-24-22-20-18-16-14-15-17-19-21-23-25-27-35-59-169(274)275)229-179(288)121(9)227-184(293)135(53-38-42-80-211)230-186(295)137(54-39-43-81-212)231-188(297)141(71-77-171(278)279)235-197(306)153(102-174(284)285)244-193(302)147(95-119(5)6)238-194(303)148(98-126-60-64-130(263)65-61-126)240-187(296)138(55-40-44-82-213)232-201(310)156(111-258)248-195(304)149(99-127-62-66-131(264)67-63-127)242-198(307)154(103-175(286)287)245-202(311)158(113-260)250-207(316)178(123(11)262)254-200(309)151(97-125-49-32-29-33-50-125)246-206(315)177(122(10)261)252-165(270)108-225-182(291)140(68-74-160(215)265)251-209(319)210(12,13)255-180(289)133(214)101-129-105-217-116-226-129/h28-33,36-37,47-52,60-67,104-105,116-123,133,135-159,176-178,221,257-264H,14-27,34-35,38-46,53-59,68-103,106-115,211-214H2,1-13H3,(H2,215,265)(H2,216,266)(H,217,226)(H,218,271)(H,219,267)(H,220,272)(H,222,269)(H,223,292)(H,224,290)(H,225,291)(H,227,293)(H,228,268)(H,229,288)(H,230,295)(H,231,297)(H,232,310)(H,233,300)(H,234,294)(H,235,306)(H,236,314)(H,237,301)(H,238,303)(H,239,305)(H,240,296)(H,241,298)(H,242,307)(H,243,299)(H,244,302)(H,245,311)(H,246,315)(H,247,312)(H,248,304)(H,249,313)(H,250,316)(H,251,319)(H,252,270)(H,253,308)(H,254,309)(H,255,289)(H,274,275)(H,276,277)(H,278,279)(H,280,281)(H,282,283)(H,284,285)(H,286,287)(H,317,318)/t121-,122+,123+,133-,135-,136-,137-,138-,139-,140-,141-,142-,143-,144-,145-,146-,147-,148-,149-,150-,151-,152-,153-,154-,155-,156-,157-,158-,159-,176-,177-,178-/m0/s1; Key:NCZIWZAVWHEUKM-SQZAUUIPSA-N;

Mazdutide (also known as IBI362 or LY3305677) is a dual agonist of the GLP-1 receptor and glucagon receptor. It is an analog of oxyntomodulin (OXM).^[1]^[2]^[3] The drug is developed by Eli Lilly and Innovent Biologics. and is currently in multiple Phase III studies.^[4]^[5] In May 2025, a result of Phase III study has shown that once-weekly mazdutide led to clinically relevant reductions in body weight in Chinese adults with overweight or obesity.^[6]

Other namesIBI362; LY3305677

Routes of
administrationInjection

Legal status

Rx in China, Investigational in general

CAS Number

2259884-03-0

Quick facts Clinical data, Other names ...

Close

In June 2025, Mazdutide injection is approved for marketing in China.^[7]

[1]

[2]

[3]

[4]

[5]

[6]

[7]

Mazdutide

References

Related Articles

Clinical data
Other names	IBI362; LY3305677
Routes of administration	Injection
Legal status
Legal status	Rx in China, Investigational in general
Identifiers
IUPAC name 20-[[(1S)-4-[2-[2-[2-[2-[2-[2-[[(5S)-5-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3R)-2-[[2-[[(2S)-5-amino-2-[[2-[[(2S)-2-amino-3-(1H-imidazol-4-yl)propanoyl]amino]-2-methylpropanoyl]amino]-5-oxopentanoyl]amino]acetyl]amino]-3-hydroxybutanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxypropanoyl]amino]hexanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-3-carboxypropanoyl]amino]-4-carboxybutanoyl]amino]hexanoyl]amino]hexanoyl]amino]propanoyl]amino]-6-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[[2-[(2S)-2-[[(2S)-1-[(2-amino-2-oxoethyl)amino]-3-hydroxy-1-oxopropan-2-yl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]amino]-2-oxoethyl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-6-oxohexyl]amino]-2-oxoethoxy]ethoxy]ethylamino]-2-oxoethoxy]ethoxy]ethylamino]-1-carboxy-4-oxobutyl]amino]-20-oxoicosanoic acid
CAS Number	2259884-03-0
PubChem CID	167312357
DrugBank	DB19099
ChemSpider	129341158
UNII	MB76Z4IBZ5
Chemical and physical data
Formula	C₂₁₀H₃₂₂N₄₆O₆₇
Molar mass	4563.141 g·mol⁻¹
SMILES CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CC[C@H](NC(=O)CCCCCCCCCCCCCCCCCCC(=O)O)C(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)C(C)(C)NC(=O)[C@@H](N)Cc1c[nH]cn1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(N)=O
InChI InChI=1S/C210H322N46O67/c1-117(2)93-145(191(300)233-139(70-76-170(276)277)181(290)224-107-164(269)222-109-168(273)256-86-46-57-159(256)204(313)249-157(112-259)203(312)247-155(110-257)183(292)223-106-161(216)266)237-192(301)146(94-118(3)4)239-196(305)152(100-128-104-221-134-52-37-36-51-132(128)134)243-190(299)143(73-79-173(282)283)236-205(314)176(120(7)8)253-199(308)150(96-124-47-30-28-31-48-124)241-189(298)142(72-78-172(280)281)234-185(294)136(56-41-45-83-218-166(271)114-322-91-90-321-88-85-220-167(272)115-323-92-89-320-87-84-219-162(267)75-69-144(208(317)318)228-163(268)58-34-26-24-22-20-18-16-14-15-17-19-21-23-25-27-35-59-169(274)275)229-179(288)121(9)227-184(293)135(53-38-42-80-211)230-186(295)137(54-39-43-81-212)231-188(297)141(71-77-171(278)279)235-197(306)153(102-174(284)285)244-193(302)147(95-119(5)6)238-194(303)148(98-126-60-64-130(263)65-61-126)240-187(296)138(55-40-44-82-213)232-201(310)156(111-258)248-195(304)149(99-127-62-66-131(264)67-63-127)242-198(307)154(103-175(286)287)245-202(311)158(113-260)250-207(316)178(123(11)262)254-200(309)151(97-125-49-32-29-33-50-125)246-206(315)177(122(10)261)252-165(270)108-225-182(291)140(68-74-160(215)265)251-209(319)210(12,13)255-180(289)133(214)101-129-105-217-116-226-129/h28-33,36-37,47-52,60-67,104-105,116-123,133,135-159,176-178,221,257-264H,14-27,34-35,38-46,53-59,68-103,106-115,211-214H2,1-13H3,(H2,215,265)(H2,216,266)(H,217,226)(H,218,271)(H,219,267)(H,220,272)(H,222,269)(H,223,292)(H,224,290)(H,225,291)(H,227,293)(H,228,268)(H,229,288)(H,230,295)(H,231,297)(H,232,310)(H,233,300)(H,234,294)(H,235,306)(H,236,314)(H,237,301)(H,238,303)(H,239,305)(H,240,296)(H,241,298)(H,242,307)(H,243,299)(H,244,302)(H,245,311)(H,246,315)(H,247,312)(H,248,304)(H,249,313)(H,250,316)(H,251,319)(H,252,270)(H,253,308)(H,254,309)(H,255,289)(H,274,275)(H,276,277)(H,278,279)(H,280,281)(H,282,283)(H,284,285)(H,286,287)(H,317,318)/t121-,122+,123+,133-,135-,136-,137-,138-,139-,140-,141-,142-,143-,144-,145-,146-,147-,148-,149-,150-,151-,152-,153-,154-,155-,156-,157-,158-,159-,176-,177-,178-/m0/s1 Key:NCZIWZAVWHEUKM-SQZAUUIPSA-N

Related Articles

"A phase 1b randomised controlled trial of a glucagon-like peptide-1 and glucagon receptor dual agonist IBI362 (LY3305677) in Chinese patients with type 2 diabetes"

"Safety and efficacy of a GLP-1 and glucagon receptor dual agonist mazdutide (IBI362) 9 mg and 10 mg in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple-ascending-dose phase 1b trial"

"IBI362 (LY3305677), a weekly-dose GLP-1 and glucagon receptor dual agonist, in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple ascending dose phase 1b study"

"Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight"